Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Overactive Bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Health Qual Life Outcomes.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR

doi: 10.1186/s12955-018-0892-0.

A systematic review of primary outcomes and outcome measure reporting in randomized trials evaluating treatments for pre-eclampsia

Int J Gynaecol Obstet.

Duffy JMN, Hirsch M, Gale C, Pealing L, Kawsar A, Showell M, Williamson PR, Khan KS, Ziebland S, McManus RJ; International Collaboration to Harmonize Outcomes for Pre-eclampsia (iHOPE)

doi: 10.1002/ijgo.12298.

Erectile and Sexual Functions and DysfunctionsHPV and Gynecologic Cancer

Sexual Morbidity Assessment in Gyne-Oncology Follow-Up: Development of the Sexual Well-Being After Cervical or Endometrial Cancer (SWELL-CE) Patient-Reported Outcome Measure

J Sex Med.

White ID, Tennant A, Taylor C

doi: 10.1016/j.jsxm.2020.06.019.

Uro-Oncology

Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection

Eur Urol.

Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, Simone G, Sciarra A, Leonardo C, Gallucci M, Catalano C, Catto JWF, Panebianco V

doi: 10.1016/j.eururo.2019.09.029.

Overactive Bladder

Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)

Adv Ther.

Carlson KV, Rovner ES, Nair KV, Deal AS, Kristy RM, Schermer CR

doi: 10.1007/s12325-

Reproductive Health

Home- or hospital-based monitoring to time frozen embryo transfer in the natural cycle? Patient-reported outcomes and experiences from the Antarctica-2 randomised controlled trial

Hum Reprod.

Zaat TR, de Bruin JP, Goddijn M, Visser J, Kaaijk EM, Lambalk CB, Groenewoud ER, van Wely M, Mol F

doi: 10.1093/humrep/deaa040.

Overactive Bladder

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Eur Urol.

Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E

doi: 10.1016/j.eururo.2019.09.024.

Overactive Bladder

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

Int Urogynecol J.

Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR

doi: 10.1007/s00192-017-3377-5.

Overactive Bladder

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment

Eur Urol.

Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E

doi: 10.1016/j.eururo.2019.07.010.

Related content

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

A systematic review of primary outcomes and outcome measure reporting in randomized trials evaluating treatments for pre-eclampsia

Sexual Morbidity Assessment in Gyne-Oncology Follow-Up: Development of the Sexual Well-Being After Cervical or Endometrial Cancer (SWELL-CE) Patient-Reported Outcome Measure

Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection

Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)

Home- or hospital-based monitoring to time frozen embryo transfer in the natural cycle? Patient-reported outcomes and experiences from the Antarctica-2 randomised controlled trial

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment